PDR 001

Drug Profile

PDR 001

Alternative Names: PD-1 inhibitor - Novartis Oncology; PDR001

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nasopharyngeal cancer
  • Phase I/II Solid tumours
  • Phase I Cancer; Lymphoma
  • Phase Unknown Hepatocellular carcinoma

Most Recent Events

  • 08 Dec 2016 Novartis Pharmaceuticals plans a phase Ib trial for Hepatocellular carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, First-line therapy) in USA, South Korea, Hong Kong, Singapore, Germany, Spain, Canada, Italy, Taiwan, Thailand, Japan and France (IV) (NCT02988440)
  • 07 Dec 2016 Investigation in Hepatocellular carcinoma in USA (IV) before December 2016
  • 16 Nov 2016 Novartis plans a phase III trial for Malignant melanoma (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT02967692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top